Generic Name: everolimus

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Novartis

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Indication

Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.


General Info

Afinitor inhibits mTOR, a serine-threonine kinase that which plays a role in cell growth and metabolism and blood vessel development.

Clinical trials showed it slows disease progression in people with HER2-negative breast cancer, kidney cancer and neuroendocrine tumors. It was first approved in 2009.


Dosage

Dosing Info: Afinitor is taken as a tablet once daily.


Side Effects

Common side effects include mouth sores, skin rash, fatigue, diarrhea, nausea, fever, swelling, headache and loss of appetite. It can cause depletion of white blood cells (neutropenia), which can lead to infections. Potential serious side effects may include lung inflammation, kidney failure, metabolic problems and severe hypersensitivity reactions. Afinitor should not be used during pregnancy.


For More Info: https://www.us.afinitor.com/

Patient Assistance Program Info: https://www.us.afinitor.com/advanced-pancreatic-neuroendocrine-tumors/patient-support/financial-resources/

Last Reviewed: December 5, 2018